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Abstract
Systemic lupus erythematosus (SLE) is rather uncommon than rare. The purpose of this study was to estimate the incidence 
and prevalence of SLE in the population of Alberta, Canada, using administrative health data. Multiple population-based 
data sources, including the Alberta Health Care Insurance Plan Central Stakeholder Registry (AHCIP CSR), Fee-For-Ser-
vice, and Hospital Discharge Abstract Database were used. Age- and sex-specific incidence and prevalence rates, and 95% 
confidence intervals (CI), were computed using the AHCIP CSR mid-year population estimates as the denominator, for the 
period of 2000–2015. The overall incidence of SLE for all age groups was 4.43 (95% CI 3.65, 5.04) per 100,000 popula-
tion. The overall incidence in male and female of all age groups was 1.26 (95% CI 0.72, 1.76) and 7.69 (95% CI 6.22, 8.81) 
per 100,000 population, respectively. A prevalence of 47.99 per 100,000 (male = 13.5, female = 83.2) of SLE was observed 
for the year 2000 and has increased to 90 (male = 25.5, female = 156.7) per 100,000 population in 2015. Over the 16-year 
period, the incidence of SLE in women was approximately six times higher than in men (odds ratio = 6.16). The highest and 
lowest incidence was recorded in 2001 and 2015, respectively. Despite the stable incidence of SLE, the findings of the study 
confirms that the prevalence of SLE has increased over the 16-year period. The increase in prevalence of SLE in Alberta 
will have an impact on health service utilizations. This finding can be used for planning and evaluating health services for 
this group of patients. Further studies are required to determine the economic burden of the condition.
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Introduction
Systemic lupus erythematosus (SLE) is a severe and chronic 
autoimmune disorder. Its cause is unknown, but it is believed 
to result from a complex interaction between genetics and 
environmental exposures [1, 2]. It affects women more than 
men and incidence tends to be highest between the ages of 
15 and 44 years [3, 4]. The incidence and prevalence of 
SLE is considerably elevated worldwide among non-white 
racial groups. For example, the prevalence of SLE among 
the Aborigine population in Australia was estimated between 
13 and 93 per 100,000 population [5].
Currently, there are few incidences and prevalences 
of SLE studies in Canada. The prevalence of SLE in the 
First Nations Population of Alberta has been estimated at 
27.3 cases and 3.2 cases per 10,000 for females and males, 
respectively [6]. The prevalence of systemic autoimmune 
rheumatic diseases (SARDs) in Alberta was 2.6 cases per 
1000 residents [1], and the prevalence of SARDs in four 
Canadian provinces (Manitoba, Quebec, Alberta and 
Saskatchewan) ranged from 15.9/100,000 in Quebec to 
23.0/100,000 in Manitoba [7]. The population-based study 
conducted to evaluate the prevalence of SLE in First Nations 
populations, in the province of Manitoba, reported that the 
prevalence of SLE was twofold (42.3 per 100,000) compared 
Rheumatology
INTERNATIONAL 
 * Francis Fatoye 
 f.fatoye@mmu.ac.uk
1 Department of Health Professions, Faculty of Health, 
Psychology, and Social Care, Manchester Metropolitan 
University, Brooks Building, 53 Bonsall Street, 
Manchester M15 6GX, UK
2 Analytics and Performance Reporting Branch, Alberta 
Health, Edmonton, Canada
3 Division of Preventive Medicine, University of Alberta, 
Edmonton, Canada
4 School of Public Health, University of Alberta, Edmonton, 
Canada
5 Department of Community Health Sciences, University 
of Calgary, Calgary, Canada
1722 Rheumatology International (2018) 38:1721–1726
1 3
to non-First Nations [8]. Further, the prevalence of SLE Brit-
ish Columbian’s Nuu-Chah-Nulth population was estimated 
at 0.3%. The Nuu-Chah-Nulth are a tribe of 2300 Pacific 
First Nations in Canada [9]. The findings of Barnabe and 
colleagues suggested that the burden of SLE was two times 
more in females above the age of 45 years than the non-First 
Nations females [6]. The population-based study in the four 
provinces of Canada also suggested that SARDs were more 
common in females than in males across all provinces [7]. 
Although the study is dated, the annual incidence of SLE in 
the First Nations populations relative to the general popula-
tions has been estimated in Alaskan Indian tribes, the annual 
incidence of SLE was 9 per 100,000 people [10].
Understanding the incidence and prevalence of SLE may 
help understand the burden associated with the condition 
and facilitate resource allocation to improve the quality of 
life of people with SLE. It may also provide clinicians and 
policy-makers with valuable information for prioritization of 
services and estimation of the impacts of policy and practice 
decisions. While there have been some studies looking at 
specific aspects of the burden of SLE in Alberta, there is 
no current systematic approach to monitoring changes in 
incidence and prevalence of SLE in Alberta. The purpose 
of the study was to estimate the incidence and prevalence of 
lupus in the Canadian province of Alberta, using routinely 
collected administrative health data.
Methods
The province of Alberta maintains a publicly funded, uni-
versally available health care system. Registration with the 
Alberta Health Care Insurance Plan (AHCIP) is mandatory 
for all residents of the province. Each resident of the prov-
ince (approximately 4.2 million) is issued a Personal Health 
Number (PHN), which acts as a unique lifetime identifier. 
The PHN is recorded for all contacts with the health care 
system and, therefore, allows for deterministic linkage across 
multiple data sources. Ethical clearance and patient writ-
ten informed consent were not required as this was a ret-
rospective review utilizing population-level administrative 
health records. All data were anonymized by the Ministry 
of Health.
Data sources
AHCIP central stakeholder registry
The AHCIP central stakeholder registry (CSR) maintains 
demographic information on all residents of the province 
eligible for health insurance coverage. This includes date 
of birth, sex, address, and postal code. Members of the 
Canadian military and federal inmates are not eligible for 
provincial health insurance coverage and were excluded 
from the study.
Fee‑for‑service
Most physicians in the province submit claims for reim-
bursement of health services provided. For those on alter-
native payment programs, a shadow claim is submitted for 
services provided. Physicians submitting claims provide 
information on the type of service provided and record up 
to three diagnostic codes, using the 9th revision of the Inter-
national Classification of Diseases (ICD-9), at the 4-digit 
level. Prior to 1994, only one diagnostic field was required 
and it used 3-digit ICD-9 coding. Other information includes 
date and location of services provided, as well as the amount 
paid to physician.
Hospital discharge abstract database
Hospital discharge abstract database (DAD) records hospital 
separations (discharge, transfer, death) and includes up to 
25 diagnostic codes. From 2003/2004 fiscal year, the cod-
ing was done using the 10th revision of the International 
Classification of Diseases—Canadian Adaptation (ICD-
10-CA). Prior to 2003/2004, the 9th revision of the Inter-
national Classification of Diseases—Clinical Modification 
(ICD-9-CM) was in use. The most responsible diagnosis, the 
one that contributed the most to length of stay, was indicated 
as well as admission and separation dates, and the type of 
services provided.
Case definition
All fee-for-service data were extracted where the ICD-9 code 
710.0 (systemic lupus erythematosus) was recorded in any 
of the three diagnostic fields, for data from 1994 to 2016. 
For data from 1983 to 1993, ICD-9 code 710 was used. For 
inpatient data, all records with either ICD-9-CM code 710.0 
or ICD-10-CA code M32.xx recorded were extracted. The 
period 1983–1994 was used as a run-in period to separate 
incident and prevalent cases. A case was defined as any 
individual that had at least three physician services, over a 
2-year period, with a minimum of 60 days between the first 
and second services, or one or more hospitalizations.
Data analysis
Age-standardized and age- and sex-specific incidence and 
prevalence estimates were computed, using the AHCIP CSR 
mid-year population estimates as the denominator. Incidence 
and prevalence estimates were age standardized, using the 
direct method, to the 1991 Canadian census population. 
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Confidence intervals were calculated using the method 
developed by Carriere and Roos [11].
Results
Prevalence
A total of 1442 cases were identified as having new or 
existing SLE for all age groups in Alberta for the year 
2000. This is equivalent to an overall prevalence of 
47.99/100,000. From this, the proportion of female 
(n = 1,237) and male (n = 205) was 83.2/100,000 and 
13.5/100,000, respectively (see Table 1).
In the year 2000, a prevalence of 112.46/100,000 
and 17.88/100,000 of SLE was identified in female and 
male over 19 years of age, respectively, in Alberta. On 
the other hand, a proportion of 2.74/100,000 in male and 
7.48/100,000 in female was identified with SLE under the 
age of 19 years (see Table 2).
The peak prevalence for male = 53.59/100,000 and 
female = 166.8/100,000 was estimated between the ages 
of 70–74 and 65–69, respectively, for the year 2000 (see 
Fig. 1). For girls under the ages of five, one patient with 
SLE was identified out of 99,328 which is equivalent to 
the point prevalence of 1/100,000. On the other hand, no 
case of SLE was identified out of 94,168 suspected SLE 
male patients under the ages of five. Generally, the preva-
lence for both male and female was observed to increase 
with age.
The trend of SLE prevalence between 2000 and 
2015 is presented below (see Fig.  2). The proportion 
of people with SLE has increased from 1442 (Popula-
tion = 3,002,917) to 3773 cases (Population = 4,193,964) 
between 2000 and 2015, respectively. In other words, in 
16 years time, the prevalence of SLE has increased by 42 
(male = 12, female = 73.5) per 100,000 population.
Table 1  The prevalence of SLE for the year 2000 in Alberta, Canada 
(per 100,000)
Sex Total population No. of cases Prevalence
Female 14,867,74 1237 83.20
Male 15,174,24 205 13.51
Total 30,041,98 1442 48.0
Table 2  The prevalence of SLE in childhood vs adult for the year 
2000 in Alberta, Canada (per 100,000)
Total population No new case Prevalence
Female < 19 years 414,374 31 7.48
Male < 19 years 437,816 12 2.74
Female > 19 years 10,724,00 1206 112.46
Male > 19 years 10,796,08 193 17.88
Fig. 1  The prevalence of SLE 
for male and female by age for 
the year 2000
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Fig. 2  The prevalence of SLE 
for male and female over 
16 years (2000–2015)
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Incidence
The overall incidence of SLE between 2000 and 2015 was 
4.43 (95% CI 3.65, 5.04) per 100,000 population. From this, 
the overall incidence of male and female was 1.3 (95% CI 
0.72, 1.76) and 7.69 (95% CI 6.22, 8.81) per 100,000 popu-
lation, respectively (see Table 3). In the year 2000, there 
were no new cases of SLE patients for both male and female 
who are less than 5 years of age (see Fig. 3). The peak inci-
dence of SLE was recorded for male (7.68/100,000) and 
female (21.75/100,000) patients aged 75–79 and 70–74, 
respectively.
The trend of SLE incidence between 2000 and 2015 is 
presented below (see Fig. 4). Compared to the year 2000, 
the incidence of SLE for both sexes in 2015 has decreased 
by 1.85 (male = 0.36, female = 3.4) per 100,000 population. 
The peak incidence of SLE (6.8/100,000) was recorded in 
the year 2001 for both male and female. The incidence of 
SLE in female between the years of 2000 and 2015 was 
approximately six times greater than their male counterpart.
The number of new cases of SLE in 2012, 2013, 
2014 and 2015 was 4.37 (male = 1.11, female = 7.73), 
4.42 (male = 1.17, female = 7.77), 4.47 (male = 1.24, 
female = 7.81) and 3.58 (male = 1.22, female = 6.01) per 
100,000 population, respectively (see Table 4). The average 
incidence difference between the consecutive years was not 
substantial, and this implies that the incidence of SLE over 
the 4-year period was approximately stable.
Discussion
The aim of the study was to estimate the incidence and 
prevalence of SLE in Alberta, Canada. It used multiple 
population-based data sources including the Alberta Health 
Care Insurance Plan Central Stakeholder Registry (AHCIP 
CSR), Fee-For-Service, and Hospital Discharge Abstract 
Database. A prevalence of 47.99 per 100,000 (male = 13.5, 
female = 83.2) of SLE was observed for the year 2000, 
and has increased to 90 (male = 25.5, female = 156.7) per 
100,000 population in 2015. This study was compared with a 
population-based study conducted in the First Nations popu-
lations of Alberta [6]. We observed the prevalence of 2.73 
cases per 100,000 female and 0.32 cases per 100,000 male 
in the First Nations populations [6]. The prevalence rate of 
SLE in the First Nations of Population was lower than the 
Table 3  The overall incidence of SLE by sex (per 100,000)
Sex Population No. of new cases Incidence
Female 1,749,741 133.4 7.60 (6.22, 8.81)
Male 1,803,354 22.6 1.30 (0.72, 1.76)
Total 3,553,095 156 4.42 (3.65, 5.04)
Fig. 3  The incidence of SLE for 
male and female by age for the 
year 2000
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Fig. 4  The incidence of SLE for 
male and female over 16 years 
(2000–2015)
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Table 4  The incidence of SLE in Alberta, Canada (per 100,000)
2012 2013 2014 2015
Total 4.37 4.42 4.47 3.58
Female 7.73 7.77 7.81 6.01
Male 1.11 1.17 1.24 1.22
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current study. This may be because the prevalence of SLE 
was estimated only from 6% of the Alberta populations who 
were ≥ 45 years. Approximately, a similar prevalence of SLE 
(42.3/100,000) to the current study was also reported in the 
Firth Nations population in Canada [8].
The prevalence in the current study was compared to 
studies conducted in United Kingdom (UK) [12] and the 
United States of America (USA) [13]. The data sources used 
for the Birmingham, UK study were the lupus patient sup-
port group, and hospital inpatient and laboratory data and 
notification by attending and the primary care physician. The 
prevalence rate of SLE (27.7/100,000) in Birmingham was 
approximately half of the prevalence rate in Alberta, Canada. 
On the other hand, the prevalence rates of SLE in California 
(107.6/100,000) and Pennsylvania (149.5/100,000) were two 
times higher than this current study [13]. The cause of the 
dramatic differences in prevalence of SLE between countries 
may be due to the methodology issues such as the size and 
type of sample used for data collection. For example, the 
current study was based on population of all age groups; 
this is because patients in Canada have no financial barriers 
to accessing healthcare, as they have in the United States. 
In addition, the environmental factors such as drugs, physi-
cal or mental stress, and air pollution may contribute to the 
high number of people with SLE in some countries. For 
example, the potential cause of SLE cases in Alberta could 
be air pollution, nitrogen dioxide and systemic autoimmune 
rheumatic disease [1].
This study is the first of its kind in Alberta to report the 
overall incidence rate of SLE using a population-based data 
collected between 2000 and 2015. The overall incidence of 
SLE for all ages in Alberta was 5.39/100,000. This observed 
incidence rate of SLE was compared to the most recent 
studies carried out in Spain [14] and Iceland [15]. The inci-
dence rate of SLE (2.15/100,000) in Spain was lower than 
in Alberta. Similar to this, the incidence rate of SLE in Ice-
land was estimated at 3.3/100,000, again this is lower than 
the present study. The possible factor for the differences in 
the incidence estimate between these studies could be the 
availability of cases of SLE to be used as a data source. 
For example, some milder cases of SLE may never present 
to hospital or be just treated as anaemia with skin rash by 
physicians.
Observation of the peak incidence rate of SLE in the 
current study for both female (21.75/100,000) and male 
(7.68/100,000) at the ages of 70–74, and 75–79 was made, 
respectively. Contrary to our study, the peak incidence 
rate of SLE in females in Birmingham, UK was reported 
between the ages of 18 and 19 years and a similar finding 
in the USA suggested the peak incidence rate of SLE was 
between the ages of 15 and 44 [12, 16]. However, studies 
from Nottingham, Sweden and Iceland have reported that the 
peak incidence rate was similar to that observed in current 
study which was between the ages of 40–49, 40–50 and 
55–74, respectively [15, 17, 18]. Reasons for discrepancies 
in reported peak incidence of SLE in different countries, 
could be explained by patient characteristics (age, race and 
socioeconomic) they consider in their study.
There are some strengths and limitations to this study. 
The strengths to this study include the data being popula-
tion based, recall bias was not an issue, any misclassification 
errors on the side of providing conservative estimates, and 
it is the first of its kind to estimate the incidence of SLE in 
Alberta. One of the limitations of the study is that our preva-
lence and incidence estimate were based on use of health 
services; the impact of this is that we may have misclassified 
or estimated cases of SLE. This study was also limited in 
taking account of the geographic distribution of cases. Fur-
ther, we do not have any data on deaths attributable to SLE, 
as a result this could not be included. Individuals that died, 
for any reason, were removed from prevalence estimates. 
Future research may include looking at the geographic dis-
tribution of cases to better assess potential environmental 
influences, direct health care costs, and pharmaceutical use.
Conclusion
This study has estimated the prevalence and incidence of 
SLE in Alberta based on multiple population-based data 
sources. It is the first of its kind to estimate for both male 
and female in all age groups of population. Despite the sta-
ble incidence of SLE, the present study confirms that the 
prevalence of SLE has increased over the 16-year period. 
The increase in prevalence of SLE in Alberta will have an 
impact on health service utilizations. This finding can, there-
fore, be used for planning and evaluating health services for 
this group of patients. Future research may include looking 
at geographic distribution of cases, direct health care costs, 
and pharmaceutical use of SLE.
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